Search Results - "Castellucci, P"

Incidental finding of [68Ga]Ga-PSMA-avid intraductal papillary mucinous neoplasm by Calabrò, D., Zanoni, L., Mosconi, C., Farolfi, A., Golfieri, R., Matteucci, F., Caroli, P., Fanti, S., Castellucci, P.

Get full text

Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study by Rojas Llimpe, F L, Di Fabio, F, Ercolani, G, Giampalma, E, Cappelli, A, Serra, C, Castellucci, P, D'Errico, A, Golfieri, R, Pinna, A D, Pinto, C

“…Background: The aim of the PROMETEO-01 Study was to define the diagnostic accuracy of imaging techniques in colorectal cancer liver metastasis (CRCLM)…”
Get full text

Imaging biomarkers in prostate cancer: role of PET/CT and MRI by Picchio, M., Mapelli, P., Panebianco, V., Castellucci, P., Incerti, E., Briganti, A., Gandaglia, G., Kirienko, M., Barchetti, F., Nanni, C., Montorsi, F., Gianolli, L., Fanti, S.

“…Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate cancer (PCa). PSA suggests the presence of primary tumour and disease…”
Get full text

Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP) by Ambrosini, V, Morigi, J J, Nanni, C, Castellucci, P, Fanti, S

“…Neuroendocrine neoplasms (NEN) functional imaging is an evolving field that witnessed major advances in the past two decades. The routine use of PET/CT with an…”
Get full text

PET/CT in prostate cancer: non-choline radiopharmaceuticals by Castellucci, P, Jadvar, H

“…In this brief review, the major potential clinical applications of 18F-FDG, 11C-acetate, 18F-FDHT, 18F-FLT, 18F-FMAU, and anti-18F-FACBC in the imaging…”
Get full text

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma by Zamagni, Elena, Nanni, Cristina, Patriarca, Francesca, Englaro, Emanuela, Castellucci, Paolo, Geatti, Onelio, Tosi, Patrizia, Tacchetti, Paola, Cangini, Delia, Perrone, Giulia, Ceccolini, Michela, Brioli, Annamaria, Buttignol, Silvia, Fanin, Renato, Salizzoni, Eugenio, Baccarani, Michele, Fanti, Stefano, Cavo, Michele

“…From the Istituto di Ematologia e Oncologia Medica "L. e A. Seràgnoli", Università di Bologna, Italia (EZ, PTo, PTa, DC, GP, MC, AB, MB, MC); Istituto di…”
Get full text

Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer by Martoni, A.A., Di Fabio, F., Pinto, C., Castellucci, P., Pini, S., Ceccarelli, C., Cuicchi, D., Iacopino, B., Di Tullio, P., Giaquinta, S., Tardio, L., Lombardi, R., Fanti, S., Cola, B.

“…2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography (FDG–PET/CT) was carried out before and after neoadjuvant…”
Get full text

Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis by Ghedini, Pietro, Bossert, I., Zanoni, L., Ceci, F., Graziani, T., Castellucci, P., Ambrosini, V., Massari, F., Nobili, E., Melotti, B., Musto, A., Zoboli, S., Antunovic, L., Kirienko, M., Chiti, A., Mosconi, C., Ardizzoni, A., Golfieri, R., Fanti, S., Nanni, C.

“…Aim During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but…”
Get full text

Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series by Francolini, G., Detti, B., Bottero, M., Zilli, T., Lancia, A., Bruni, A., Borghesi, S., Mariotti, M., Castellucci, P., Fanti, S., Filippi, A. R., Teriaca, M. A., Maragna, V., Aristei, C., Mazzeo, E., Livi, L., Ingrosso, G.

“…Aims 68 Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We…”
Get full text

Endotracheal metastasis from colorectal cancer by Tabacchi, E., Ghedini, P., Cambioli, S., Castellucci, P., Fanti, S.

“…A 46-year-old woman with an history of colon cancer treated with left hemicolectomy, chemotherapy, radiotherapy and pulmonary nodule resections was referred…”
Get full text

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients by Zinzani, P. L., Tani, M., Fanti, S., Alinari, L., Musuraca, G., Marchi, E., Stefoni, V., Castellucci, P., Fina, M., Farshad, M., Pileri, S., Baccarani, M.

“…Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. Patients and Methods:…”
Get full text

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients by Derenzini, E., Fina, M.P., Stefoni, V., Pellegrini, C., Venturini, F., Broccoli, A., Gandolfi, L., Pileri, S., Fanti, S., Lopci, E., Castellucci, P., Agostinelli, C., Baccarani, M., Zinzani, P.L.

“…Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care…”
Get full text

The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? by Schiavina, R, Ceci, F, Borghesi, M, Brunocilla, E, Vagnoni, V, Gacci, M, Castellucci, P, Nanni, C, Martorana, G, Fanti, S

“…Only few patients with PSA relapse after radical treatment will show clinically detectable disease. Although the natural history of recurrent prostate cancer…”
Get more information

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients by Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G., Castellucci, P., Marchi, E., Farsad, M., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Bacci, F., Pileri, S., Baccarani, M.

“…Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and…”
Get full text

EP-1049: Prognostic role of 18F-FDG PET/CT in head and neck cancers treated with radical radio-chemotherapy by Sandler, I, Castellucci, P, Fanti, S, Caliceti, U, Frakulli, R, Milani, A, Cammelli, S, Deodato, F, Nuzzo, M, Macchia, G, Frezza, G, Morganti, A.G

Get full text

18F–FDG PET/CT scan confirmed by pathology findings in a singular case of squamous cell carcinoma of the epiglottis by Lima, G. M., Matti, A., Burgio, L., Nanni, C., Castellucci, P., Fanti, S.

“…Background Only about 1% of all head and neck lateral or paramedian cancers described in the scientific literature shows, in staging, contralateral cervical…”
Get full text

Determination of the activity meter calibration factor for Rhenium-188 by Liverani, S., Vichi, S., Zagni, F., Riga, S., Lima, G. M., Castellucci, P., Wendler, T., Olmeda, M., Marengo, M., Mostacci, D.

“…An innovative epidermal surface treatment based on 188 Re has been recently developed for squamous cell carcinomas of the skin. The planning and delivery of…”
Get full text

PO-0644: 11C-methionine PET-CT for contouring and response evaluation of head and neck tumors treated with CIRT at CNAO by Bonora, M, Fossati, P, Fiore, M.R, Iannalfi, A, Vischioni, B, Vitolo, V, Ciurlia, E, Molinelli, S, Mirandola, A, Gallio, E, Russo, S, Panizza, D, Ciocca, M, Rodari, M, Olivari, L, Chiti, A, Nanni, C, Castellucci, P, Fanti, S, Krengli, M, Ronchi, S, Valvo, F, Orecchia, R

Get full text

[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy by Martoni, A A, Fanti, S, Zamagni, C, Rosati, M, De Iaco, P, D'Errico Grigioni, A, Castellucci, P, Quercia, S, Musto, A, Ricci Maccarini, L, Lopci, E, Bernardi, A

“…The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a…”
Get full text

Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: How to differentiate local from systemic disease? The urologist point of view by Schiavina, R., Brunocilla, E., Borghesi, M., Vagnoni, V., Castellucci, P., Nanni, C., Ceci, F., Gacci, M., Martorana, G., Fanti, S.

“…About 40% of all patients undergoing radical treatment for localized prostate cancer (PCa) develop biochemical relapse (BCR) during lifetime but only 10–20% of…”
Get full text